BioSpace News Archive

Hoth Therapeutics announced today the addition of Dr. Richard D. Granstein, M.D., to the Company’s Technology Advisory Board.

Rebiotix today announced new clinical findings from the RBX2660 Phase 2 program that are being presented in three poster presentations at the World Congress of Gastroenterology at ACG2017 in Orlando, Fl.

AAVP Biosystems, a development stage gene therapy company focused on the pursuit of new targeted therapeutics for cancer indications, is pleased to announce the formation of its Medical Advisory Board.

Takeda today announced the presentation of data suggesting early symptomatic improvement in specific symptoms with Entyvio (vedolizumab) in patients with moderately to severely active ulcerative colitis (UC) or Crohn’s disease (CD), particularly in biologic-naïve patients for whom other therapies have not worked well enough.

Regeneron and Sanofi today announced positive results from a Phase 2 investigational study of dupilumab in adults with active moderate-to-severe eosinophilic esophagitis.

Medizone Internationalor Medizone, manufacturer of the AsepticSure Disinfection System, today announced that it is now allowed to place the “CE” Mark on the AsepticSure System

Concordia today announced that in conjunction with its ongoing efforts to realign its capital structure, it has decided to use a 30-day grace period to defer the payment of approximately $26M of interest due today on its $735M unsecured notes.

Ardelyx today reported that data from preclinical studies have shown that tenapanor works to reduce abdominal pain caused by irritable bowel syndrome with constipation (IBS-C) through the inhibition of TRPV-1 dependent signaling

Ambry Genetics Corporation (Ambry), a leading genetic testing lab, will be participating at the American Society of Human Genetics Annual Meeting (ASHG).

ImmunoGen, Inc. today announced that the U.S. Food and Drug Administration (FDA) has completed the safety review of its investigational new drug (IND) application for IMGN632 in patients with CD123-positive hematological malignancies.